This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Sponsor: Memorial Sloan Kettering Cancer Center
Permitted histologies include:
i) Stage ≥Ib CTCL, which has relapsed or progressed after at least two systemic therapies.
For the following histologies, patients are required to have received at least 1 prior therapy:
xii) Primary cutaneous anaplastic large cell lymphoma
xiii) Primary cutaneous gamma/delta T-cell lymphoma
xiv) Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT05010005